Diazoxide improves muscle function in association with improved dyslipidemia and decreased muscle oxidative stress in streptozotocin-induced diabetic rats

• Published in: Journal of bioenergetics and biomembranes 2023-02, Vol.55 (1), p.71-78
• Main Authors: Vargas-Vargas, Manuel Alejandro, Saavedra-Molina, Alfredo, Gómez-Barroso, Mariana, Peña-Montes, Donovan, Cortés-Rojo, Christian, Rodríguez-Orozco, Alain R., Rocío, Montoya-Pérez
• Format: Article
• Language: English
• Subjects: Animal Anatomy; Animal Biochemistry; Animal models; Animals; Biochemical characteristics; Biochemistry; Biomarkers; Bioorganic Chemistry; Chemistry; Chemistry and Materials Science; Cholesterol; Cholesterol - metabolism; Damage assessment; Diabetes; Diabetes mellitus; Diabetes Mellitus, Experimental - complications; Diazoxide - adverse effects; Diazoxide - metabolism; Dyslipidemia; Fatigue; Fluorescence; Glutathione; Histology; Hyperglycemia; Hyperglycemia - complications; Insulin; Insulin secretion; Lipids; Lipoproteins; Metabolic disorders; Mice; Morphology; Muscle function; Muscle strength; Muscle, Skeletal - metabolism; Muscles; Muscular fatigue; Organic Chemistry; Oxidation; Oxidative Stress; Oxygen; Potassium channels; Rats; Rats, Wistar; Reactive oxygen species; Reactive Oxygen Species - metabolism; Signs and symptoms; Skeletal muscle; Soleus muscle; Streptozocin; Streptozocin - adverse effects; Streptozocin - metabolism; Thiobarbituric acid; Thiobarbituric Acid Reactive Substances - adverse effects; Thiobarbituric Acid Reactive Substances - metabolism; Triglycerides; Triglycerides - adverse effects; Triglycerides - metabolism
• ISSN: 0145-479X; 1573-6881
• DOI: 10.1007/s10863-023-09958-7

Aim/Introduction: Diabetes Mellitus is a chronic degenerative disease, and its main biochemical characteristic is hyperglycemia due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Hyperglycemia causes dyslipidemia and stimulates oxidative damage, leading to the main symptoms, such as fatigue and culminates in diabetic complications. Previous studies have shown that ATP-sensitive potassium channels counteract muscle fatigue and metabolic stress in healthy mouse models. To determine the effect of diazoxide on muscle strength development during diabetes, we tested the effect of diazoxide in streptozotocin-diabetic rats in muscle function, lipid profile and oxidative stress biomarkers. Materials and methods: Wistar rats were divided into 4 groups of six animals each: (1) Control group, (2) diabetes group, (3) Control group + diazoxide, and (4) Diabetic + diazoxide (DB + DZX). 4 weeks after rats were sacrificed, soleus and extensor digitorum longus muscles (EDL) were extracted to prepare homogenates and serum was obtained for biochemical measurements. Oxidative damage was evaluated by the thiobarbituric acid method and the fluorescent for reactive oxygen species (ROS) probe 2,4-H 2 DCFDA, respectively. Results: Diabetic rats with diazoxide administration showed an increase in the development of muscle strength in both muscles; in turn, the onset of fatigue was longer compared to the group of diabetic rats without treatment. Regarding the lipid profile, diazoxide decreased total cholesterol levels in the group of diabetic rats treated with diazoxide (x̅46.2 mg/dL) compared to the untreated diabetic group (x̅=104.4 mg/dL); secondly, diazoxide decreased triglyceride concentrations (x̅=105.3 mg/dL) compared to the untreated diabetic rats (x̅=412.2 mg/dL) as well as the levels of very low-density lipoproteins (x̅=20.4 mg/dL vs. x̅=82.44 mg/dL). Regarding the various markers of oxidative stress, the diabetic group treated with diazoxide was able to reduce the concentrations of TBARS and total reactive oxygen species as well as preserve the concentrations of reduced glutathione. Conclusion: Diazoxide administration in diabetic rats increases muscle strength development in EDL and soleus muscle, decreases fatigue, reduces cholesterol and triglyceride concentrations and improves oxidative stress parameters such as TBARS, ROS, and glutathione status.